This year, Amgen is hosting six Science without Borders undergraduate interns at its Thousand Oaks, California headquarters.
The Science without Borders program is a Brazilian scholarship program that seeks to train 101,000 students and researchers in top universities worldwide in science, technology, engineering and math (STEM) fields by 2014.
The Amgen internship program will provide students with a unique opportunity to experience the biotechnology industry. There was considerable interest in the programme with a high level of well qualified applicants. Through a process of selection and interviews those applicants were whittled down to the six candidates ultimately recruited.
The students will work in one of four different functional areas: Research & Development, Information Systems, Global Strategic Sourcing and International Commercial Operations.
“I feel like I am a true part of the company and department, and doing something that matters. Compared to previous research experiences I’ve had, the amount of communication between team members and departments is really high. Everyone is aware of what others are doing. It’s much more integrated, which makes work flow more efficiently. I want to acquire experience in drug discovery. Working at Amgen is a unique chance, and I want to make a good impression, do my best work and show my potential.” – Felipe de Oliveira
Meet the Students:
Dayanne Castro is from Fortaleza, the capital city of the state of Ceará in the northeastern corner of Brazil. Dayanne is hosted by the University of Pennsylvania in Philadelphia. Her home university is the State University of Campinas, where she studies biology. She is working in Amgen’s Research and Development department evaluating the use of molecular modeling software to drive the engineering of antibodies for therapeutics.
Israel Matos is from Florianopolis, the capital city of the state of Santa Catarina in southern Brazil. Washington State University is hosting Israel in the United States, and the Federal University of Santa Catarina is his home university. He is studying biology. Israel is working in Research and Development at Amgen, evaluating biomarkers of kidney injury.
Marina Santos is from Belo Horizonte, the capital of the state of Minas Gerais in southeastern Brazil. Marina attends the Federal University of Minas Gerais and, in the United States, the University of Missouri in Kansas City. Her area of study is pharmacy. Marina is interning in the Latin America/Canada/Australia regional commercial team in Thousand Oaks, CA. In this role, she is assisting our Brazilian affiliate’s quality and drug development leaders in reviewing local processes and developing improvement recommendations.
Felipe de Oliveira is from Campinas in São Paulo state in southeastern Brazil. His host university is the University of Michigan in Ann Arbor, and his home university is the State University of Campinas, where he studies biology. Felipe is working in Amgen’s Research and Development department, focused in neuroscience on examining the contribution of ion channels to pain and migraine.
Danillo Oliveira is from Diamantina in the state of Minas Gerais in a mountainous area in southeastern Brazil. In the United States, Danillo attends Iowa State University in Ames. In Brazil, he attends the Federal University of Minas Gerais, where he studies industrial engineering. He can be found in is working in Information Systems at Amgen and is involved in drafting project plans and creating quick reference guides for Amgen applications.
Felipe Coelho is from Manaus, the capital city of the state of Amazonas in northern Brazil. Felipe is hosted by Auburn University in Auburn, Alabama. In Brazil, he attends Amazonas State University, studying industrial engineering. At Amgen, Felipe can be found in Global Strategic Sourcing, where he is working on budget planning and productivity efforts.
Amgen, a biotechnology company, discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.